Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial-Reference-Cited by-同舟云学术

Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial

Published:2018-12 Issue:10165 Volume:392 Page:2705-2717
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Sanyal Arun,Charles Edgar D,Neuschwander-Tetri Brent A,Loomba Rohit,Harrison Stephen A,Abdelmalek Manal F,Lawitz Eric J,Halegoua-DeMarzio Dina,Kundu Sudeep,Noviello Stephanie,Luo Yi,Christian Rose

Publisher

Elsevier BV

Subject

General Medicine

Reference42 articles.

1. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases;Chalasani;Hepatology,2017

2. Global epidemiology of nonalcoholic fatty liver disease—meta-analytic assessment of prevalence, incidence, and outcomes;Younossi;Hepatology,2016

3. NASH cirrhosis—the new burden in liver transplantation: how should it be managed?;Canbay;Visc Med,2016

4. Nonalcoholic fatty liver disease: a systematic review;Rinella;JAMA,2015

5. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD;Hagstrom;J Hepatol,2017

Cited by 415 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Computer-aided engineering of stabilized fibroblast growth factor 21;Computational and Structural Biotechnology Journal;2024-12

2. Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities;European Journal of Medicinal Chemistry;2024-11

3. Endocrine fibroblast growth factors in domestic animals;Domestic Animal Endocrinology;2024-10

4. FGF21 agonists: An emerging therapeutic for metabolic dysfunction-associated steatohepatitis and beyond;Journal of Hepatology;2024-09

5. Maladaptive regeneration and metabolic dysfunction associated steatotic liver disease: Common mechanisms and potential therapeutic targets;Biochemical Pharmacology;2024-09